Definium Therapeutics (DFTX) CEO Robert Barrow Sells 31,550 Shares

What Happened Robert Barrow, CEO of Definium Therapeutics (DFTX), sold 31,550 common shares on September 25, 2026. The reported weighted-average price was $36.57 per share, for total gross proceeds of approximately $1,153,784. The sale was reported as an S (sale) transaction and was executed to satisfy tax withholding related to vested restricted stock units.

Key Details

• Transaction date: September 25, 2026 (Form filed September 29, 2026 — filing appears timely)
• Shares sold: 31,550
• Reported weighted-average price: $36.57; total proceeds ≈ $1,153,784
• Price range: $36.24 to $36.98 (shares were sold in multiple transactions on that date)
• Reason/footnotes:
  • F1: Shares sold to satisfy withholding tax on settled vested RSUs pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted June 15, 2022.
  • F2: Weighted-average price reported; the filer can provide per-trade prices on request.
• Shares owned after the transaction: not specified in the provided filing excerpt

Context This was a sell-to-cover sale tied to tax withholding on vested restricted stock units (a common, routine transaction for insiders), executed under a pre-established Rule 10b5-1 plan. Such sales are generally administrative and do not, by themselves, indicate the insider's view on the company's outlook.